Democrats such as Elizabeth Warren had their eye on business and the working class during the first 2020 presidential primary debate in Miami.2020 Electionsread more
The issue over health insurance marked the first stark divide among the candidates, and sparked a heated back-and-forth between many of the candidates on stage.Politicsread more
Huawei's legal chief told CNBC that the company makes "solutions for civil use."Technologyread more
Four candidates mentioned China — but none of the Democratic contenders brought up trade in the debate.Politicsread more
In a strategy to draw attention away from Wednesday's Democratic debate, President Donald Trump's reelection campaign bought out YouTube's "masthead," the leading...2020 Electionsread more
The Federal Aviation Administration said on Wednesday that is has found an issue with the Boeing 737 Max that the manufacturer must address before it lifts the grounding...Airlinesread more
The collapse of the deal potentially ended Sinclair's hopes of building a national conservative-leaning TV powerhouse that might have rivaled Fox News.Mediaread more
Virginia Sen. Mark Warner breaks down the idea behind a bipartisan bill he introduced to provide more transparency in Big Tech.Technologyread more
Tesla is working on new battery cell designs, and a way to make their own cells, with R&D teams in a lab near its car plant in Fremont, California.Technologyread more
These attacks have given the public the opportunity to examine the problems associated with ransomware, where corporations -- not obligated to disclose these attacks -- have...Technologyread more
Wi-Fi 6 will be the next-generation wireless standard. Along with 5G, it will represent the next big shift in connectivity and data, said Irving Tan, senior vice president and...Shaping the futureread more
Richard Peterson, senior director of global markets intelligence with S&P Capital IQ, told CNBC's "Squawk on the Street " on Monday that things are different this time around.
"Back in the heyday, many of the deals had no revenue [potential], let alone earnings," he said. "There were 46 tech IPOs priced in 2000, and last year there were 34. "
He also noted the good story in health care mergers and acquisitions activity, which he expects to increase over the coming years as the population ages.
Jason Kolbert, Maxim biotechnology analyst, told CNBC's "Squawk Alley " Monday that fears of a biotech bubble aren't that scary.
"The market hates uncertainty, but what do we have today in biotech? More visibility than we've ever had before," he said.
Kolbert attributes his confidence to a lower clinical trial failure rate as well we a higher FDA approval rate.
"I think the odds are going up. We're gambling a little bit, but we understand the science at a level that we've never understood it before."